主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMTX
#6995
Immatics N.V. Ordinary Shares
10.340
0
+4.23%
版块:
基础:
利润货币:
日范围
年范围
日变化
+4.23%
每月变动
+3.19%
6个月变化
-0.10%
年变化
-0.10%
前一天收盘价
9.920
0
Open
10.340
0
Bid
Ask
Low
10.340
0
High
10.340
0
交易量
18
市场
股票
医疗保健
IMTX
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
62.91 M
62.93 M
76.67 M
84.66 M
121.55 M
345.81 M
Valuation ratios
Enterprise value
678.78 M
845.74 M
657.07 M
907.53 M
864.22 M
3.27 B
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
新闻
Immatics Stock: PRAME Leader’s Transition To Commercial Reality (NASDAQ:IMTX)
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Salesforce and Micron Tech among market cap stock movers on Friday
Micron, Salesforce among market cap stock movers on Friday
Leerink Partners将Immatics目标价从16美元上调至17美元
Immatics stock price target raised to $17 from $16 at Leerink Partners
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)
Company News for Nov 18, 2025
古根海姆上调Immatics股票目标价至19美元,看好TCR管线数据
Guggenheim raises Immatics stock price target to $19 on positive TCR pipeline data
Immatics NVQ3每股收益及营收逊于预期
Immatics NV earnings missed by €0.04, revenue fell short of estimates